Investing Profile

Kush Parmar


Managing Partner at 5AM Ventures

5amventures.comBoston, Massachusetts
Photo of Kush Parmar, Managing Partner at 5am Ventures

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
5am Ventures Managing Partner
$100K - $5.0M
CompanyStageDateRound SizeTotal Raised
Series AFeb 2021$70M
Co-investors: Stephen Knight (F-Prime Capital Partners)
Vor Biopharma
Series BJul 2020$110M
Series AFeb 2019$42M
Series AAug 2018$25M
Seed RoundNov 2017$7.5M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), Heather Preston (Pivotal bioVenture Partners)
Cleave Therapeutics
Series BAug 2016$26M
Co-investors: Robert Garland (New Enterprise Associates (NEA)), Carol Gallagher (New Enterprise Associates (NEA)), Andrew Schwab (5am Ventures), Peter Thompson (OrbiMed), Marc Singer (Osage University Partners), Larry Lasky (The Column Group), Alfred Scheidegger (Nextech Invest)
Series BOct 2015$42M
Series ASep 2013$15M
Co-investors: Colleen Cuffaro (Canaan Partners), Stephen Squinto (OrbiMed), Tim Shannon (Canaan Partners), Andrew Levin (RA Capital), Jakob Loven (Nextech Invest), Daniel Wagner (Connecticut Innovations), Liam Ratcliffe (Access Biotechnology)
Audentes Therapeutics
Series COct 2015$65M
Series BDec 2014$43M
Co-investors: Stephen Squinto (OrbiMed), Jonathan Silverstein (OrbiMed), Tom Woiwode (Versant Ventures), Jonathan Leff (Deerfield Management)